MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
MyoKardia Inc at the at the RBC Capital Markets 2018 Healthcare Conference (Replay)
February 21, 2018 at 8:30 a.m. ET
Recent Press Releases
02/14/18MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
NASDAQ GS | MYOK (Common Stock)
$56.75 - 0.5
02/23/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.